Trial Profile
A Randomized, Double-Blind, Placebo-Controlled Phase 2a Study to Evaluate the Efficacy and Safety of Tildrakizumab in Subjects with Active Ankylosing Spondylitis or Non-Radiographic Axial Spondyloarthritis
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 12 May 2023
Price :
$35
*
At a glance
- Drugs Tildrakizumab (Primary)
- Indications Ankylosing spondylitis; Non-radiographic axial spondyloarthritis
- Focus Therapeutic Use
- Sponsors Sun Pharma Global FZE; Sun Pharmaceutical Industries
- 10 May 2023 Results (n=101) assessing efficacy and safety of tildrakizumab in patients with ankylosing spondylitis published in the JCR: Journal of Clinical Rheumatology
- 05 Jun 2019 Status changed from active, no longer recruiting to discontinued.
- 22 May 2019 This trial has been discontinued in Spain, according to European Clinical Trials Database.